SCHEMBL5339277

SCHEMBL5339277

CC(C)(C)OC(=O)n1ccc2cc(C(N)=S)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.45
ABL1 P00519 2/20 0.45
EGFR P00533 2/20 0.45
HCK P08631 2/20 0.45
SRC P12931 2/20 0.45
KDR P35968 2/20 0.45
PIK3CA P42336 2/20 0.45
PIK3CB P42338 2/20 0.45
MTOR P42345 2/20 0.45
PIK3CG P48736 2/20 0.45
EPHB4 P54760 2/20 0.45
PRKDC P78527 2/20 0.45
PI4KB Q9UBF8 2/20 0.45
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
BUB1 O43683 1/20 0.36
TUBB1 Q9H4B7 2/20 0.36
NR1H2 P55055 3/20 0.36
NR1H3 Q13133 1/20 0.35
HTR6 P50406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6394140 0.85 PIK3CD (0.45) PIK3CDABL1EGFRHCKSRC
SCHEMBL1623656 0.85 PIK3CD (0.45) PIK3CDABL1EGFRHCKSRC
SCHEMBL13262833 0.85 PIK3CD (0.44) PIK3CDABL1EGFRHCKSRC
SCHEMBL1057530 0.83 PIK3CD (0.44) PIK3CDABL1EGFRHCKSRC
SCHEMBL30066410 0.83 PIK3CD (0.44) PIK3CDABL1EGFRHCKSRC
SCHEMBL312329 0.81 PIK3CD (0.51) PIK3CDABL1EGFRHCKSRC
SCHEMBL3387968 0.80 CA12 (0.43) PIK3CDABL1EGFRHCKSRC
SCHEMBL1468882 0.80 PIK3CD (0.42) PIK3CDABL1EGFRHCKSRC
SCHEMBL1881676 0.80 PIK3CD (0.42) PIK3CDABL1EGFRHCKSRC
SCHEMBL1468880 0.80 PIK3CD (0.42) PIK3CDABL1EGFRHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PIK3CD 3375/4885ABL1 1729/4885EGFR 2468/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PIK3CD 3375/4885ABL1 1729/4885EGFR 2468/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX PIK3CD 3375/4885ABL1 1729/4885EGFR 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.